A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Verified

Overview

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma.

SparkCures ID 1081
Trial Phase Phase 1
Enrollment 150 Patients
Treatments
Tags
Trial Sponsors
  • Juno Therapeutics, a Subsidiary of Celgene
NCT Identifier

NCT04394650

CLOSED

This trial is active but is no longer accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Signed written informed consent prior to any study procedure.
  3. Relapsed and/or refractory multiple myeloma (MM). Subjects must have received at least 3 prior antimyeloma treatment regimens and be refractory to the last regimen prior to study entry. Subjects must have previously received all of the following therapies:
    1. Autologous stem cell transplant
    2. A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or combination
    3. Anti-CD38 (eg, daratumumab), either alone or combination
  4. Measurable disease
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  6. Adequate organ function

Exclusion Criteria:

  1. Known active or history of central nervous system (CNS) involvement of MM
  2. Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis
  3. Prior treatment with CAR T-cell or another genetically modified T-cell therapy
  4. Prior treatment with therapy directed at BCMA
  5. Uncontrolled or active infection
  6. Active autoimmune disease requiring immunosuppressive therapy
  7. History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers
SparkCures Verified

SparkCures is working closely with Juno Therapeutics, a Subsidiary of Celgene to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors